With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in navigating challenges like ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Repatha alone contributed a 40% sales increase ... Looking forward, Amgen maintains its 2024 revenue guidance between $33 billion and $33.8 billion, with a non-GAAP EPS range of $19.20 to $ ...

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. On the contrary -- this can ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Amgen is a leading drugmaker with a lineup of medicines across many therapeutic areas. In 2024, the company had 13 products that each generated more than $1 billion in sales. True, some of them ...